Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report

A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JTO clinical and research reports 2024-10, Vol.5 (10), p.100712, Article 100712
Hauptverfasser:	Patel, Shetal A., Whang, Young, Medley, Chaely, Chen, Kevin, Jordan, Jasmine, Bortone, Dante, Vincent, Benjamin, Weiss, Jared
Format:	Artikel
Sprache:	eng
Schlagworte:	Bispecific T-cell engager Case Report Cytokine release syndrome DLL3 Large cell neuroendocrine carcinoma Tarlatamab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.
ISSN:	2666-3643 2666-3643
DOI:	10.1016/j.jtocrr.2024.100712